Business
Blackstone Life Sciences and Anthos Therapeutics Announce Novartis has Completed the Acquisition of Anthos Therapeutics in a Deal Valued at up to $3.1B, with $925M Paid Upfront
CAMBRIDGE, Mass., April 03, 2025--Blackstone Life Sciences and Anthos Therapeutics, Inc., a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases, announced today that Novartis has completed its acquisition of Anthos Therapeutics in a transaction valued at up to $3.1 billion.
About this update from Blackstone Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1651,"height":646,"url":"https://media.zenfs.com/en/business-wire.com/26dd1b39a99e8aeccb04fea08d63ece3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LqY8KRA3Y8YrMKDjVdVAAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3NjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/26dd1b39a99e8aeccb04fea08d63ece3","width":960,"height":376},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/c4N0V2LY82GwgpkoK8xM5g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/26dd1b39a99e8aeccb04fea08d63ece3","width":1200,"height":470}},"lazy":false},{"type":"text","content":"The deal affirms Blackstone’s vision of building companies around innovative products to meet unmet patient needs","length":113,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass., April 03, 2025--(BUSINESS WIRE)--Blackstone Life Sciences and Anthos Therapeutics, Inc., a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases, announced today that Novartis has completed its acquisition of Anthos Therapeutics in a transaction valued at up to $3.1 billion.","length":374,"tagName":"p"},{"type":"text","content":"Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel Factor XI inhibitor that originated at Novartis. Abelacimab is currently in Phase 3 clinical development for the prevention of stroke and systemic embolism in patients with atrial fibrillation (LILAC-TIMI 76), in addition to two phase 3 studies in patients with cancer-associated thrombosis (ASTER and MAGNOLIA). Data from these trials are expected in the second half of 2026.","length":554,"tagName":"p"},{"type":"text","content":"Transaction Details","length":19,"tagName":"p"},{"type":"text","content":"Anthos shareholders will receive up to $3.1 billion in total deal value, including an upfront payment of $925 million, and payments in the event certain regulatory and commercial milestones are achieved.","length":203,"tagName":"p"},{"type":"text","content":"Advisors","length":8,"tagName":"p"},{"type":"text","content":"Goldman S...